MGTA News and Press, Magenta Therapeutics Inc. From 12/04/20

Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickl...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the appointment of Steve Mahoney as Chief Financial and Operating Officer. “We welcome ...

Magenta Therapeutics (MGTA): Q3 GAAP EPS of -$0.37 beats by $0.08.Cash, cash equivalents and marketable securities of $161.7MPress Release For further details see: Magenta Therapeutics EPS beats by $0.08

– Magenta advanced its MGTA-145 mobilization program, with two Phase 2 trials to be initiated by end of 2020; the Company’s MGTA-117 conditioning program is on track to file an IND and generate clinical data in 2021; – Magenta announced appointment of Lisa...

– Magenta will present a total of five abstracts, including an oral presentation highlighting clinical and preclinical data across its mobilization and conditioning pipeline – – Oral presentation of completed Phase I clinical trial confirms that MGTA-145, ...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company will participate in the following September investor conferences: Cantor Virtual Glob...

Magenta Therapeutics ( MGTA -3.1% ) is a co-recipient of a five-year $14.6M NIH grant aimed at exploring the use of gene therapies and cell-based therapies to cure HIV. More news on: Magenta Therapeutics, Inc., Healthcare stocks news, Read more ...

– NIH grant funds an interdisciplinary effort among researchers from University of Southern California; University of Washington and Fred Hutchinson Cancer Research Center; Harvard University and Massachusetts General Hospital; the Ragon Institute; and Magenta Therapeutics – ...

Magenta Therapeutics (NASDAQ: MGTA ) has appointed two new executives , Lisa M. Olson, Ph.D., as Chief Scientific Officer and Kevin B. Johnson, Ph.D., as SVP, Head of Regulatory and Quality. More news on: Magenta Therapeutics, Inc., Healthcare stocks news, Read more ...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the appointment of two new executives, Lisa M. Olson, Ph.D., as Chief Scientific Officer and Kevin B. Johnso...